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A B S T R A C T
Overexpression of survivin is observed in various hematological malignancies, including acute myeloid
leukemia (AML). Studies show that elevated expression of survivin correlateswith aworse clinic outcome
in AML patients. It remains unclear whether inhibition of survivin may alter the eﬃcacy of chemother-
apy against AML. Here, we evaluate the effects of speciﬁc knockdown of survivin on AML cells’ sensitivity
to chemotherapy, and investigate the therapeutic potential of the transcription inhibitor of survivin YM155
either alone or in combination with chemotherapeutic agents. We found Kasumi-1 and HL-60 cells had
relatively higher expression levels of survivin among all AML cell lines tested. Speciﬁc knockdownof survivin
in Kasumi-1 and HL-60 cells resulted in: inhibition of cell proliferation; cell cycle G2/M arrest; induction
of DNA damage response and apoptosis. Downregulation of survivin enhanced etoposide- or doxorubicin-
induced anti-proliferative/anti-survival activity in AML cells. The smallmolecule inhibitor YM155 reduced
survivin in a dose- and time-dependent manner and trigged apoptosis in Kasumi-1 and HL-60 cells. The
combinatorial effects of YM155 and chemotherapeutics were either synergetic or antagonistic, depend-
ing upon the drugs used for combination and the type of AML cells being treated. Collectively, our data
demonstrate that survivin plays an important role in the maintenance and proliferation of AML cells.
While speciﬁc knockdown of survivin enhances chemosensitivity, the combinations of YM155 and che-
motherapeutic agents exhibit synergetic or antagonistic effects onAML cells. Our ﬁndings provide a rationale
for further assessment of survivin-targeted therapy in the treatment of patients with AML.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Survivin (coding gene: BIRC5), the smallest mammalian member
of IAP (inhibitor of apoptosis) family, is a dual functional protein
acting as a critical apoptosis inhibitor and key cell cycle regulator
[1]. The anti-apoptotic function of survivin is mainly via inhibi-
tion of caspase-9, with help of a cellular protein named hepatitis
B X-interacting protein (HBXIP) [2]. It also forms a complex with
XIAP to stabilize XIAP from ubiquitination/proteasomal destruction
[3]. As a cell cycle regulator, expression of survivin peaks at G2/M
phase, regulatingmitosis within amulti-protein complex called chro-
mosomal passenger complex (CPC), ensuring accurate segregation
of sister chromatids [4,5]. Survivin is usually expressed in embry-
onic tissues during development and undetectable inmost terminally
differentiated tissues. It has also been detected in some normal pro-
liferating adult tissues and cells, such as hematopoietic stem/
progenitor cells, vascular endothelial cells, T cells, erythroid cells,
ovary, testes, and liver [6]. Overexpression of survivin is observed
in a wide variety of human cancers and the increased survivin is
correlated with a poor clinic outcome, tumor recurrence, and ther-
apeutic resistance [7–9]. For instance, we have shown that
overexpression of erbB3 receptor confers paclitaxel resistance in
erbB2-overexpressing breast cancer cells via PI-3K/Akt-dependent
upregulation of survivin [10]; and targeting of erbB3 with a ther-
apeutic antibody (Ab) re-sensitizes the breast cancer cells to
paclitaxel treatmentmainly through downregualtion of survivin [11].
Elevated expression of survivin and its correlation with adverse
clinical outcome has also been found in hematological malignan-
cies, including diffuse large B-cell lymphoma (DLBCL), childhood
B-cell precursor acute lymphoblastic leukemia, multiple myeloma
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(MM), BCR-ABL positive chronicmyeloid leukemia (CML), adult T-cell
leukemia/lymphoma (ATL), anaplastic large-cell lymphoma (ALCL),
and acute myeloid leukemia (AML) [12]. It has been shown that
survivin was upregulated in AML cells by hematopoietic cytokines,
like GM-CSF, G-CSF and SCF, via MAPK and PI-3K signaling path-
ways [13]. Survivin-speciﬁc antisense oligonucleotides induced
growth inhibition and cell death in HL-60 cells [14]. In another study,
the expression of survivin was detected by a validated reverse-
phase protein array in samples from 511 newly diagnosed AML
patients. Detailed analysis discovered signiﬁcantly higher levels of
survivin in CD34+38− AML stem/progenitor cells than in bulk blasts
and total CD34+ AML cells; and the higher levels of survivin asso-
ciated with a shorter overall and event-free survival [15].
Furthermore, the expression of survivin correlated with the ex-
pression of multiple proteins involved in proliferation and cell
survival, supporting the role of survivin as a prognostic marker and
a potential therapeutic target in AML [15].
YM155 (Astellas Pharma US, Inc., Northbrook, IL) is a small mol-
ecule suppressant of survivin transcription. It competes the binding
sites of Sp1 on survivin promoter [16] and thereby disrupts the ILF3
transcriptional complex [17,18]. Clinical trials of YM155 used as a
single agent or in combination with other drugs have been carried
out in various solid tumors, including non-small cell lung cancer
[19,20], prostate cancer [21] and melanoma [22]. In hematologi-
cal malignancies, phase II clinical trials of YM155 as monotherapy
in DLBCL showed weak eﬃcacy [23]. Recent studies with mouse
models of human B-Cell non-Hodgkin lymphoma or adult T-cell leu-
kemia revealed that YM155 in combination with monoclonal
antibody Rituximab (anti-CD20) [24] or alemtuzumab/Campath-
1H (anti-CD25) [25], respectively, showed signiﬁcant improvements
in tumor regression and survival. Thus, corresponding clinical trials
are ongoing in CD20-positive B cell non-Hodgkin’s lymphoma pa-
tients (NCT01007292) and ATL patients (NCT00061048). To date, no
clinical studies initiated to test the therapeutic potential of YM155
in AML patients. In current report, we evaluated the inﬂuence of
survivin silencing on AML cell proliferation and chemosensitivity.
We also investigated the inhibitory effects of YM155 alone or in com-
bination with chemotherapeutic agents on AML cells.
Materials and methods
Reagents and antibodies
YM155 was purchased from Selleck Chemicals (Houston, TX, USA). Doxorubi-
cin was purchased from ALEXIS Biochemicals (San Diego, CA, USA). Cytarabine (Pﬁzer
Inc., New York, NY, USA.) and etoposide (Hengrui Medicine CO. LTD, Jiangsu, China)
were obtained from pharmacy of Institute of Hematology and Blood Disease Hos-
pital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Tianjin,
China. YM155 and etoposide were dissolved in dimethyl sulfoxide (DMSO) to make
a stock solution at 20 mmol/L. Cytarabine and doxorubicin were dissolved in water
to make a stock solution at 20 mmol/L and 10 mmol/L, respectively. All the stock
solutions were stored at −80 °C.
MISSION Non-target shRNA, which does not target human and mouse genes,
control vector (pLKO.1-ConshRNA), pLKO.1 containing human survivin shRNA (pLKO.1-
SurshRNA) were purchased from Sigma (St. Louis, MO, USA). Clone IDs of survivin
targeting shRNAs used in our studies were: TRCN0000073720S (S3), TRCN0000073721
(S4) and TRCN0000222542 (S5). The packaging plasmids psPAX2 and pMD2.G for
lentiviral expression vector were from Addgene (Cambridge, MA, USA).
Antibodies were obtained as follows: Survivin (6E4) mouse mAb, Bcl-2 rabbit
Ab, Bcl-xL rabbit Ab, caspase-3 rabbit mAb (8G10), caspase-8 mouse mAb (1C12),
PARP rabbit mAb, P-Histone H2A.X (Ser139) rabbit Ab, Histone H2A rabbit polyclonal
Ab II, P-CHK2 (Thr68) rabbit polyclonal Ab, and CHK2 rabbit polyclonal Ab (Cell Sig-
naling Technology, Inc., Beverly, MA), and β-actinmousemAb (AC-75) (Sigma Chemical
Co.). All other reagents were purchased from Sigma unless otherwise speciﬁed.
Cells and cell culture
Human acute myeloid leukemia (AML) cell lines Kasumi-1, HL60, NB4 and U937
were maintained in our laboratory. All cell lines were maintained in RPMI1640 cell
culture medium supplemented with 10% fetal bovine serum (FBS) at a 37 °C hu-
midiﬁed atmosphere containing 95% air and 5% CO2 and were split twice a week.
Quantiﬁcation of apoptosis
An apoptosis ELISA kit (Roche Diagnostics Corp., Indianapolis, IN) was used to
quantitatively measure cytoplasmic histone-associated DNA fragments
(mononucleosomes and oligonucleosomes) as previously reported [11,26].
Flow cytometric analysis of cell cycle
Flow cytometric analyses were performed to deﬁne the cell cycle distribution
for treated and untreated cells [26,27]. In brief, cells grown in 100mm culture dishes
were harvested and resuspended in cold PBS, ﬁxed with 9 volumes of 70% ethanol.
Cells were then stained for total DNA content with a solution containing 50 μg/mL
propidium iodide, 50 μg/mL RNaseA, 0.1% Triton X-100 and 0.1 mmol/L EDTA in PBS
for 30 min at 37 °C. Cell cycle distribution was analyzed at the Flow Cytometry Core
Facility of University of Colorado Cancer Center with a FACScan ﬂow cytometer (BD
Biosciences, San Jose, CA).
Reverse transcription-PCR and quantitative real-time (qRT)-PCR
Total RNAwas extracted using amodiﬁed chloroform/phenol procedure (TRIZOL®,
Invitrogen, Carlsbad, CA). First-strand cDNAwas generated using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) following the man-
ufacturer’s instructions. The expression of human survivin mRNA (forward primer:
5′-GCCCAGTGTTTCTTCTGCTT-3′; reverse primer: 5′-TCTCCGCAGTTTCCTCAAAT-3′) was
examined by both conventional reverse transcription-PCR and qRT-PCR as we de-
scribed previously [28]. The qRT-PCR was performed using the Absolute* Blue QPCR
Master Mixes (Thermo Fisher Scientiﬁc Inc., Waltham, MA) according to the man-
ufacturer’s protocol. The expression of β-actin mRNA (forward primer: 5′-
AGAGCTACGAGCTGCCTGAC-3′; reverse primer: 5′-AGCACTGTGTTGGCGTACAG-3′) was
used as an internal control. All qRT–PCR reactions were carried out on a 7500 Fast
Real-Time PCR system (Applied Biosystems).
Western blot analysis
Protein expression or activation was determined byWestern blot analyses as pre-
viously described [11,26]. The Coomassie Plus protein assay reagent (Thermo Fisher
Scientiﬁc Inc.) was used to measure the protein concentration of total cell lysates.
Equal amounts of cell lysates were boiled in Laemmli SDS-sample buffer, resolved
by SDS–PAGE, subjected to Western blot analysis with speciﬁc primary antibodies
as described in the ﬁgure legends. After the blots were incubated with horseradish
peroxidase-labeled secondary antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA), signals were detected using the enhanced chemiluminescence re-
agents (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Cell proliferation assays
The CellTiter96™ AQ non-radioactive cell proliferation kit (Promega Corp.,
Madison, WI) was used to evaluate cell viability as previously described [26,27]. In
brief, cells were plated on 96-well plates with 0.1 mL complete medium contain-
ing 5% FBS as control, or 0.1 mL of the same medium with either YM155, etoposide,
doxorubicin or cytarabine alone, or their combinations, and incubated for 48 hr in
a cell culture incubator. After reading all wells at 490 nm with a microplate reader,
the percentages of surviving cells from each group relative to controls, deﬁned as
100% survival, were determined by reduction of MTS.
Statistical analysis
Statistical analyses of the experimental data were performed using a two-
sided Student’s t test. Signiﬁcancewas set at a P < 0.05. Calculation of IC50, combination
index (CI) and evaluation of synergy or antagonism between YM155 and chemo-
therapeutic agents were performed as described in literature [29] using the CompuSyn
software (ComboSyn, Inc., Paramus, NJ, USA).
Results
Different expression of survivin is observed in AML cells and higher
levels of survivin correlate with a worse overall survival in
AML patients
To strengthen the hypothesis that survivin may be developed as
a valuable target in the treatment of AML patients, we ﬁrst exam-
ined the expression levels of survivin in several human AML cell
lines. Western blot analyses showed strikingly high levels of survivin
in Kasumi-1 and HL-60 cells as compared to U-937 and NB4 cells
(Fig. 1A). It appeared that Kasumi-1 cells also expressed high levels
of Bcl-2 and Bcl-xL, the other two well-known, functionally related
anti-apoptotic proteins, whereas HL-60 cells had highest Bcl-2 levels
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and the least expression of Bcl-xL among the AML cell lines tested
(Fig. 1A). We next performed PCR analyses of survivin mRNA to
explore whether the high protein levels of survivin were due to a
mechanism involved in gene transcription. Both conventional reverse
transcription-PCR (Fig. 1B) and quantitative real-time (qRT)-PCR
(Fig. 1C) assays revealed that the expression of survivin mRNA was
much higher in Kasumi-1 and HL-60 cells than that in U-937 and
NB4 cells, suggesting that the expression of survivin in AML cells
might be regulated at transcriptional level. To further assess the sig-
niﬁcance of survivin expression in AML, we analyzed the TCGA
dataset of AML patient samples. By utilizing the University of Cal-
ifornia Santa Cruz (UCSC) Cancer Genomics Browser (https://
genome-cancer.ucsc.edu), we generated Kaplan–Meier survival
curves following the description in literature [30] and discovered
Fig. 1. Elevated expression of survivin is observed in AML cell lines, and associated with a worse survival in AML patients. (A) Four AML cell lines in logarithmic phase were
collected and subjected to (B) Western blot analyses with speciﬁc antibody directed against survivin, Bcl-2, Bcl-xL or β-actin. (B) Total RNA extracted from the AML cell
lines was subjected to ﬁrst-strand cDNA synthesis using a reverse transcription kit from Applied Biosystems. The partial coding sequence of survivin and β-actin was am-
pliﬁed with speciﬁc primers. The PCR products were separated on a 1% agarose gel containing ethidium bromide and visualized under a UV light. Densitometry analyses of
the signals were carried out. The arbitrary numbers indicate the ratio of survivin:β-actin for each sample. (C) The mRNA levels of survivin were measured by qRT-PCR. Data
show the relative expression levels of survivin in each cell line as compared to that in U937, deﬁned as 1. (D) Kaplan–Meier plot generated from UCSC Cancer Genomics
Browser. The AML patients from TCGA database with higher expression levels of survivin mRNA (red line) have a worse overall survival than those with basal expression
levels of survivin mRNA (green line). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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that the AML patients with higher expression of survivin (red line)
had a worse overall survival than those with basal expression of
survivin (green line) (Fig. 1D). These data provide a strong ratio-
nale to use Kasumi-1 and HL-60 as a valuable cell model to
corroborate survivin as a molecular target for AML therapy.
Silencing of survivin induces growth inhibition, cell cycle G2/M
arrest, and apoptosis in AML cells
To study the inﬂuence of survivin expression on AML cell main-
tenance and proliferation, we infected Kasumi-1 and HL-60 cells
with the lentivirus containing either non-targeted control shRNA
or survivin-speciﬁc shRNA. As compared to control, all three se-
quences of survivin-speciﬁc shRNA (S3, S4, S5) markedly
downregulated survivin expression in Kasumi-1 and HL-60 cells at
48 hr and 72 hr post lentiviral infection (Fig. 2A). The shRNAs we
used were speciﬁc for survivin, as they had no signiﬁcant inhibi-
tory effect on Bcl-2 and Bcl-xL in both Kasumi-1 and HL-60 cells.
These data are consistent with our previous ﬁndings in human breast
cancer cells [10]. It seemed that the expression levels of Bcl-xL were
slightly increased in Kasumi-1 cells at 72 hr post lentiviral infec-
tion (Fig. 2A), which might be a compensatory induction upon
survivin downregulation. However, this phenomenon was not seen
in HL-60 cells. Importantly, speciﬁc knockdown of survivin signiﬁ-
cantly reduced proliferation of both Kasumi-1 and HL-60 cells
(Fig. 2B). Especially in Kasumi-1 cells, the cell survival rate tested
on day 5 of survivin knockdown (with shRNA-S3 and S5) was lower
than that on day 3, suggesting a possibility of cell death. This ob-
servation was supported by an early report showing that decreased
expression of survivin with antisense oligonucleotides promoted
myeloid leukemia cells undergoing apoptosis through a mitochon-
drial pathway [14].
Since survivin plays a pivotal role in cell cycle regulation [4,5],
wenextperformedﬂowcytometryanalyses (Fig. 3AandB) toexamine
whether downregulation of survivin blocked cell cycle progres-
sion, and thus contributing to the growth inhibitory effects. As
compared to control shRNA, knockdown of survivin with speciﬁc
shRNAs dramatically increased the cell population at G2/M phase
(S3 and S4 in Kasumi-1 cells, S3 and S5 in HL-60 cells). This obser-
vation is in agreement with the unique feature of survivin, whose
expression is cell cycle-dependent, peaks at G2/M phase, and ex-
ecutes its function as an indispensable regulator of cellmitosis [1,31].
These data suggest that cell cycle G2/M arrest may contribute to
survivin knockdown-induced growth inhibition in AML cells. As per-
turbedmitoticprogress inhibits acute segregationof sister chromatids,
which can cause DNA damage and lead to mitotic catastrophe and
eventual cell death, we then investigated whether speciﬁc knock-
down of survivin in AML cells would cause DNA damage and
apoptosis. We found that the phosphorylation levels of H2A.X
(γH2A.X) andCHK2 (P-CHK2), twowell-knownDNAdamagemarkers,
increased upon reduction of survivin in both Kasumi-1 and HL-60
cells (Fig. 3C). In comparison to the changes of P-CHK2, dramatic
induction of γH2A.X was observed, with the most profound
upregulation caused by the survivin-speciﬁc shRNA S3, consistent
with the ﬁndings that shRNA-S3 was the most effective sequence
to downregulate survivin and induce cell cycle G2/M arrest (Fig. 3A
and B). Furthermore, speciﬁc knockdown of survivin also pro-
moted AML cells undergoing apoptosis, evidenced by PARP cleavage
Fig. 2. Speciﬁc knockdown of survivin expression inhibits cell proliferation. Kasumi-1 and HL-60 cells infected with lentivirus containing either ConshRNA (Con) or SurshRNA
(S3, S4, and S5) were subjected to the following experiments. (A) After 48 hr or 72 hr lentiviral infection, cells were collected and subjected to Western blot analyses with
speciﬁc antibody directed against survivin, Bcl-2, Bcl-xL, or β-actin. (B) After 48 hr lentiviral infection, cells were plated onto 96-well plates at the density of 8000 cell/well,
MTS assays were performed to examine cell growth. All wells were read at 490 nM with a microplate reader on Days 1, 3, and 5. Reading of Day 1 was set as control. Curves
show the relative proliferation rates of cells.
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Fig. 3. Speciﬁc knockdown of survivin expression induces cell cycle G2/M arrest in AML cells. Kasumi-1 and HL-60 cells were infected with lentivirus containing either
ConshRNA (Con) or SurshRNA (S3, S4, and S5). (A and B) After 48 hr, cells were collected and subjected to ﬂow cytometric analysis of cell cycle distribution. Data show the
representative of three independent experiments. (C) After 48 or 72 hr, cells were collected and subjected to Western blot analyses with speciﬁc antibody directed against
survivin, γH2A.X (Ser139), H2A.X, P-CHK2 (Thr68), CHK2, or β-actin.
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(Fig. 4A), a hallmark of apoptosis and signiﬁcant increases in DNA
fragments (Fig. 4B). Theenhancedcleavageof caspase-8andcaspase-3
suggested that survivin knockdown-induced apoptosis in Kasumi-1
and HL-60 cells might be caspase dependent (Fig. 4A). Collectively,
our data indicate that silencing of survivin blocks AML cells to go
through G2-M checkpoint or halt at mitotic phase, and thereby
induces cell cycle G2/M arrest and apoptosis.
Downregulation of survivin enhances chemotherapy-induced DNA
damage response and apoptosis in AML cells
To further explore survivin as a useful target in AML treatment,
we next investigated if knockdown of survivin would enhance
chemotherapy-mediated anti-proliferative/anti-survival effects on
AML cells. Kasumi-1 and HL-60 cells were infectedwith the lentivirus
Fig. 4. Speciﬁc knockdown of survivin expression promotes AML cells undergoing apoptosis. Kasumi-1 and HL-60 cells infected with lentivirus containing either ConshRNA
(Con) or SurshRNA (S3, S4, and S5) for 48 or 72 hr were collected and subjected to Western blot analyses with speciﬁc antibody directed against caspase-8 (Pro-Casp-8,
full-length caspase-8; C-Casp-8, cleaved caspase-8), caspase-3 (Pro-Casp-3, full-length caspase-3; C-Casp-3, cleaved caspase-3), PARP (F-PARP, full-length PARP; C-PARP,
cleaved PARP), or β-actin (A), or a speciﬁc apoptosis ELISA (B). Bars, SD.
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containing either control shRNA or survivin-speciﬁc shRNAs. After
24 hr, the cells were then treated with etoposide or doxorubicin,
the commonly used chemotherapeutics in AML for another 24 hr.
As compared to the control cells treated with etoposide, speciﬁc
knockdown of survivin clearly increased PARP cleavage and acti-
vation of caspase-8 and caspase-3 triggered by etoposide (Fig. 4A),
and signiﬁcantly enhanced etoposide-induced DNA fragmenta-
tion (Fig. 4B). Western blot assays discovered that downregulation
of survivin in combination with etoposide markedly increased
P-CHK2 and γH2A.X in Kasumi-1 and HL-60 cells, respectively.
However, it only led to a slight induction of P-CHK2 in HL-60 cells
and of γH2A.X in Kasumi-1 cells. There were no signiﬁcant changes
on expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL. Similar
results of the molecular markers of apoptosis and DNA damage re-
sponse were also observed in Kasumi-1 cells treated with
doxorubicin (Supplementary Fig. S1). Interestingly, both the levels
of P-CHK2 (Thr68) and electrophoretic mobility of CHK2 reduced
in Kasumi-1 cells upon doxorubicin treatment (Supplementary
Fig. S1), implying that the phosphorylation of CHK2 might occur on
the residues other than Thr68. Previous report regarded Thr68 as
the ﬁrst phosphorylation site of CHK2 after doxorubicin treat-
ment, which was subsequently followed by phosphorylation on
Ser33/35 [32]. Phosphorylation on multiple sites of CHK2 would
probably decrease its electrophoretic mobility. Our data indicated
that speciﬁc knockdown of survivin signiﬁcantly enhanced chemo-
sensitivity in AML cells, providing a theoretical basis to facilitate the
development of a novel combinatorial approach to treat patients
with AML.
The transcriptional inhibitor of survivin YM155 induces growth
inhibition, DNA damage response, and apoptosis in AML cells
To identify a feasible tool for clinical use in targeting of survivin,
we considered YM155, a small molecule inhibitor of survivin tran-
scription. YM155 exhibits potent inhibitory effect on survivin
promoter [33]; and it is currently under phase I and II clinical trials
in various solid tumors and lymphoma [19–23]. To date, no clinic
study is initiated to test the therapeutic potential of YM155 in AML
patients. Thus, we sought to evaluate if YM155 could speciﬁcally
downregulate survivin and induce apoptosis in AML cells. First, we
treated Kasumi-1 and HL-60 cells with different concentrations of
YM155, and found that YM155 inhibited proliferation of Kasumi-1
(Fig. 5A) and HL-60 (Fig. 6A) in a dose-dependent manner. The IC50
values of YM155 were 40.6 nmol/L and 2.5 nmol/L for Kasumi-1 and
HL-60 cells, respectively. Next, we examined if YM155 could inhibit
survivin expression in the two cell lines. While the expression levels
of survivin were downregulated by YM155 in a dose- and time-
dependent manner, the expression of Bcl-2 and Bcl-xL was not
affected (Fig. 6B and data not shown for HL-60). Third, we studied
if YM155 could promote AML cells undergoing apoptosis. Treat-
ment of Kasumi-1 cells with YM155 enhanced PARP cleavage and
activation of both caspase-8 and caspase-3 (Fig. 6C), and in-
creased histone-associated DNA fragments quantiﬁed by an
apoptotic-speciﬁc ELISA (Fig. 6D). Similar results were also ob-
served in HL-60 cells (Fig. 7B and C). These data suggest that YM155-
induced apoptosis in AML cells was caspase-dependent. In addition,
studies on the molecular markers of DNA damage response showed
an increased γH2A.X (Ser139) and P-CHK2 (Thr68) in both Kasumi-1
and HL-60 cells upon YM155 treatment (Figs. 6C and 7B). As DNA
damage response was a consequential event of cell cycle G2/M arrest
in the studies of survivin knockdown with speciﬁc shRNAs (Fig. 3),
we wondered if YM155-induced DNA damage response was due to
its capability to inhibit survivin. Analysis of cell cycle distribution
revealed that YM155mainly reduced the cells at S phase and slightly
increased the cells at G1 and G2/M phases (Supplementary Fig. S2),
implying a major effect on DNA synthesis. Thus, the DNA damage
response seemed to be a direct event of YM155 treatment, inde-
pendent from the reduction of survivin. Collectively, these results
indicated that YM155 inhibited survivin expression and induced
apoptosis and DNA damage response in AML cells in a dose- and
time-dependent manner. It appeared that the apoptotic cell death
and DNA damage response triggered by YM155 did not result ex-
clusively from survivin downregulation.
YM155 in combination with chemotherapeutics exhibits synergistic
or antagonistic effects on AML cells
As aforementioned, speciﬁc downregulation of survivin en-
hanced chemosensitivity and YM155 inhibited survivin expression
in AML cells. We next explored the anti-proliferative/anti-survival
effects of YM155 in combination with chemotherapeutic agents on
AML cells. Etoposide, doxorubicin, and cytarabine were used either
alone or combined with a ﬁxed ratio with YM155 to treat Kasumi-1
cells for 48 hr. A signiﬁcant growth inhibition was observed upon
treatments with etoposide plus YM155 or doxorubicin plus YM155,
as compared to single agent (Fig. 8A left). The potential outcomes
for combining two agents may be synergistic, additive, or antago-
nistic, which can be determined by the values of combination index
(CI) [34]. The values of CI quantitatively depict synergism (CI < 1),
additive effect (CI = 1), or antagonism (CI > 1). To determine if YM155
in combination with etoposide or doxorubicin may have synergis-
tic effects on Kasumi-1 cells, we performed CI analyses using the
CompuSyn software according to the Chou–Talalay equation [29].
YM155 plus etoposide showed a synergistic effect over a wide range
of concentrations. YM155 in combination with doxorubicin exhib-
ited a potent synergistic activity with CI well below 1.0 (Fig. 8A right).
The combinatorial effect of YM155 and cytarabine was slightly better
than either agent alone under certain concentrations (Supplementary
Fig. S3). CI analysis found that YM155 and cytarabine exhibited a
synergistic activity over a limited range of concentrations (CI < 1).
Their antagonistic activity, however, covered a wide range of con-
centrations (CI > 1) (Supplementary Fig. S3). Similar studies were
also performed in HL-60 cells. It seemed that HL-60 cells were very
sensitive to the treatments of YM155 alone, whereas the combi-
natorial treatments did not do signiﬁcantly better than YM155 alone
(Fig. 8B left). Although all the combinations appeared to be more
effective than single agent to inhibit proliferation of HL-60 cells, the
CI analyses discovered antagonistic effects for the combination of
YM155 and etoposide. YM155 in combination with doxorubicin
showed antagonistic effects over a wide range of concentrations, and
it had addictive or weak synergetic effects in a very limited
range of concentrations (Fig. 8B right). Taken together, our data
demonstrated that the combinatorial effects of YM155 and chemo-
therapeutic agents could be synergetic or antagonistic, depending
upon the drugs used and the AML cells tested. The concentrations
of the drugs also inﬂuenced the CI index. Further investigation is
warranted to seek optimal regimens containing YM155 for AML
therapy. When applying YM155 into clinic practice, the subtypes
of AML need to be taken into consideration for selecting the most
effective treatments.
Discussion
Survivin is selectively expressed in tumor, but not normal tissues
[1,31]. Increased survivin associates with a poor clinic outcome,
tumor recurrence, and drug resistance in cancer patients [7–9]. It
is believed that inhibition/downregulation of survivin should be a
valuable strategy for cancer treatment. Indeed, several approaches
targeting of survivin, including the transcriptional inhibitors, an-
tisense oligonucleotide (ASO), immunotherapy, and gene therapy
have been developed [7,8,35], and some of them are under clini-
cal trials in various human cancers (http://www.clinicaltrials.gov).
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It is worth mentioning that survivin does exist in some, although
not many normal tissues. In hematopoietic system, expression of
survivin has been found in CD34+ stem and progenitor cells [36–38],
T lymphocytes [39,40], polymorphonuclear neutrophils [41], and
vascular endothelial cells [42]. In adult, survivin is indispensable
for the proliferation and maintenance of hematopoietic stem and
progenitor cells [38]. Survivin also plays a vital role in the devel-
opment of megakaryocyte/erythroid progenitors [43]. During the
differentiation process of megakaryocyte/erythroid progenitors, the
expression levels of survivin vary according to the destination of
cell. A relatively higher level of survivin is critical for proper ery-
throid differentiation, whereas downregulation of survivin is required
for terminal differentiation of megakaryocytes [38,43]. Thus, when
choosing a survivin-targeted therapy for hematological malignan-
cies, its inﬂuence on normal hematopoiesis needs to be taken into
consideration.
LY2181308 (Eli Lilly and Co., Indianapolis, IN) and Terameprocol/
EM-1421 (Erimos Pharmaceuticals, Houston, TX) are survivin-
targeted agents under clinical investigation in human cancers.
LY2181308 is a 2′-O-methoxymethyl modiﬁed ASO targeting survivin
mRNA. Its clinical activity as monotherapy or in combination with
idarubicin or cytarabine has been tested in refractory/relapsed AML
patients. LY2181308 was well tolerated as single agent, and showed
some clinical beneﬁts and no additional toxicity in combination with
chemotherapy [44]. Terameprocol is a transcriptional repressor of
survivin promoter. Its suppressive effect on survivin is based upon
inhibition of the transcription factor Sp1 [45]. While phase I clin-
ical trials of Terameprocol in refractory/relapsed AML patients have
been completed, phase II studies are ongoing [46]. To date, tar-
geted therapy of AML has only been used for PML-RARα positive
acute promyelocytic leukemia (APL) with all-trans retinoic acid
(ATRA) in the clinic. Chemotherapy remains the ﬁrst line treat-
ments for majority of the subtypes of AML [47]. In the current study,
we not only demonstrated that survivin was essential for the main-
tenance and proliferation of AML cells, but also showed that targeting
of survivin with either speciﬁc shRNAs or a transcriptional sup-
pressant YM155markedly enhanced chemosensitivity against AML.
YM155 downregulated survivin and promoted AML cells undergo-
ing apoptosis in a dose- and time-dependent manner. The
combinatorial effects of YM155 and chemotherapeutic agents can
be synergetic or antagonistic, depending on the drugs used for com-
bination and the type of AML cells. As a transcriptional inhibitor
Fig. 5. Downregulation of survivin enhances etoposide-induced apoptosis and DNA damage response in AML cells. Kasumi-1 and HL-60 cells infected with lentivirus con-
taining either ConshRNA (Con) or SurshRNA (S3, S4, and S5) for 24 hr were then untreated or treated with etoposide (Kasumi-1: 2.5 μmol/L; HL-60: 0.4 μmol/L) for additional
24 hr. Cells were collected and subjected to Western blot analyses of survivin, Bcl-2, Bcl-xL, caspase-8, caspase-3, PARP, γH2A.X (Ser139), H2A.X, P-CHK2 (Thr68), CHK2, or
β-actin (A), or a speciﬁc apoptosis ELISA (B). Bars, SD.
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of survivin, YM155 shows potent anticancer ability in vitro, with a
profound induction of cell death in various cancer cells at nanomolar
levels [33,48]. In a phase II study of YM155 as single agent in 41
patients with refractory DLBCL, only 1 patient had a complete re-
mission and 2 patients responded with a median progression-free
survival of 58 days, indicating a very limited effect in DLBCL [23].
Phase II studies with YM155 as monotherapy had also been carried
out in other solid tumors. Adverse events of YM155 as single therapy
were well tolerated, however, its antitumor activities were modest
[19–22]. Our data suggest that survivin as a promising target, YM155,
may be best used in combination with the drugs showing syner-
getic effects for the treatment of AML.
Meanwhile, the speciﬁcity of YM155 has been challenged [35].
Glaros et al. ﬁrst reported that YM155 was a DNA damaging agent
rather than a transcriptional suppressor of survivin, because the con-
centrations of YM155 required to induce γH2AX and P-KAP1, two
Fig. 6. YM155 downregulates survivin and induces apoptosis and DNA damage response in Kasumi-1 cells. (A) Kasumi-1 cells were plated onto 96-well plates with 0.1 mL
1640 medium containing 5% FBS as control, or 0.1 mL of the same medium with indicated concentrations of YM155, and incubated for 48 hr in a cell culture incubator.
After reading all wells at 490 nM with a microplate reader, the percentages of surviving cells from each group relative to control, deﬁned as 100% survival, were determined
by reduction of MTS. (B–D) Kasumi-1 cells were cultured in 1640 medium with 5% FBS containing 0, 20, 40, or 80 nmol/L of YM155 for 24 hr, or in 1640 medium with 5%
FBS containing 40 nmol/L of YM155 for 0, 16, or 24 hr. Cells were collected and subjected to Western blot analyses of survivin, Bcl-2, Bcl-xL, or β-actin (B), or Western blot
analyses of caspase-8, caspase-3, PARP, γH2A.X (Ser139), H2A.X, P-CHK2 (Thr68), CHK2 or β-actin (C), or a speciﬁc apoptosis ELISA (D). Bars, SD.
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Fig. 7. YM155 downregulates survivin and induces apoptosis and DNA damage response in HL-60 cells. (A) The response curve of HL-60 cells to YM155 was generated by
MTS assays. (B and C) HL-60 cells were cultured in 1640 medium with 5% FBS containing 0, 2 or 4 nmol/L of YM155 for 24 hr, or cultured in 1640 medium with 5% FBS
containing 2.5 nmol/L of YM155 for 0, 24, or 48 hr. Cells were collected and subjected to Western blot analyses of survivin, caspase-8, caspase-3, PARP, γH2A.X (Ser139),
H2A.X, P-CHK2 (Thr68), CHK2, or β-actin (B) or a speciﬁc apoptosis ELISA (C). Bars, SD.
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Fig. 8. YM155 in combination with chemotherapeutic agents exhibits synergistic or antagonistic effects on growth inhibition of AML cells. Kasumi-1 (A) or HL-60 (B) cells
were plated onto 96-well plates with fresh medium (5% FBS) or the same medium containing indicated concentrations of YM155, etoposide, or doxorubicin alone, or the
combinations of etoposide and YM155, or doxorubicin and YM155 with a ﬁxed ratio for 48 hr. The percentages of surviving cells as compared to controls, deﬁned as 100%
survival, were determined by reduction of MTS. The combination index (CI) curves were calculated using CompuSyn software according to the Chou–Talalay equation.
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hallmarkers of DNA damage response, were much lower than that
needed to inhibit survivin [49]. YM155-induced downregulation of
survivin was likely a secondary event following DNA damage. It was
shown that YM155 did not induce cell cycle G2/M arrest, but reduced
early DNA synthesis in a humanMerkel cell carcinoma cell lineMKL-
1. In addition, YM155 only decreased the growth rate of MKL-1
xenografts and the tumors grew back when YM155 was with-
drawn [50]. In our studies, we found that YM155, unlike speciﬁc
knockdown of survivin with shRNAs, did not arrest Kasumi-1 cells
at G2/M, rather decreased cell population in S phase (Supplementary
Fig. S2). Our data support YM155 as a DNA damaging agent to inhibit
DNA synthesis. Although U-937 and NB4 cells express much lower
levels of survivin than Kasumi-1 and HL-60 cells (Fig. 1), we per-
formed the same MTS assays to examine the inhibitory effects of
YM155 on U-937 and NB4 cells and found that they exhibited a
similar sensitivity to YM155 as compared to Kasumi-1 and HL-60
cells (Data not shown). These results may partially attribute to the
non-speciﬁcity of YM155. It is likely that survivin is not the only
factor predicting for YM155 sensitivity. Other genetic/epigenetic al-
terations may also contribute to the anti-proliferative effects of
YM155 on AML cells. Thus, it is understandable that the mecha-
nisms of action, the speciﬁcity and the potency of YM155 in human
cancers are under intensive interrogation. More detailed investi-
gations are warranted to test the clinic activity of YM155 in AML
as monotherapy or in combination with other drugs. Although
YM155 may function with “off-target” effects, if AML patients could
beneﬁt from YM155 treatment, it would still be a valuable thera-
peutic option for AML patients.
In summary, we show that survivin plays a vital role for themain-
tenance and proliferation of AML cells. Therapeutic targeting of
survivin is a useful strategy against AML. YM155, the transcrip-
tional inhibitor of survivin, in combination with chemotherapeutic
agents exhibits either synergetic or antagonistic effects depen-
dent upon the drugs or AML cells used. Our ﬁndings provide a strong
rationale for in vivo testing and clinical assessment of survivin-
targeted therapy in the treatment of patients with AML.
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